Background
Belcher Pharmaceuticals holds U.S. Patent No. 9,283,197, directed to an epinephrine formulation with a pH between 2.8 and 3.3. Epinephrine (adrenaline) is used in emergency medicine for conditions such as anaphylaxis and cardiac arrest, and the patent covered a more stable and better-tolerated injectable formulation. Belcher sued Hospira under the Hatch-Waxman Act, alleging infringement of the ‘197 patent.
During the district court proceedings, Hospira raised an inequitable conduct defense. The evidence showed that while prosecuting the ‘197 patent before the USPTO, Belcher’s Chief Science Officer, Darren Rubin, was simultaneously interacting with the FDA regarding prior epinephrine products already on the market. Specifically, Rubin used information about existing competitor epinephrine products — including their pH ranges — in submissions to the FDA to help support Belcher’s own regulatory application. Despite being aware that those prior products were within or closely adjacent to the pH range he was claiming as novel, Rubin never disclosed this information to the USPTO during patent prosecution.
The district court found the ‘197 patent unenforceable for inequitable conduct, specifically finding that Rubin (1) made material misrepresentations to the USPTO about the criticality of the claimed pH range, and (2) withheld known, material prior art in the form of the competing epinephrine products. Belcher appealed.
The Court’s Holding
The Federal Circuit affirmed. The court found substantial evidence supporting both elements of inequitable conduct: materiality and specific intent to deceive.
On materiality, the prior epinephrine products and the information disclosed to the FDA about them were highly material to the patentability of the ‘197 claims. A reasonable patent examiner would have wanted to know that a competitor’s product already operated within or near the claimed pH range — exactly the information that Rubin had in hand but did not share with the USPTO.
On intent, the court found that Rubin’s conduct crossed the line from mere negligence or oversight into deceptive intent. He had actively changed Belcher’s pH range to match the prior products for FDA purposes while simultaneously claiming that range as novel and non-obvious before the USPTO. The court found this was not an inadvertent omission; Rubin knew about the prior products, knew they were relevant, and chose not to disclose them.
Because both elements were satisfied, the court affirmed that the ‘197 patent was unenforceable for inequitable conduct and that Belcher could not enforce it against Hospira.
Key Takeaways
- Inequitable conduct requires both materiality (the withheld information would have been important to the examiner) and specific intent to deceive — and courts will infer intent from circumstantial evidence when the only reasonable explanation is deceptive purpose.
- Information disclosed to the FDA during regulatory proceedings about prior art or competing products may be independently material to the USPTO — applicants cannot create firewalls between their FDA and patent prosecution activities.
- Patent applicants’ chief scientists and executives who are involved in both regulatory and patent prosecution activities bear a heightened duty of disclosure to ensure consistency and completeness.
- A finding of inequitable conduct renders the patent entirely unenforceable — not just partially invalid — making it one of the most severe consequences in patent law.
Why It Matters
Inequitable conduct is sometimes called the “inequitable conduct plague” because defendants raise it frequently but courts sustain it relatively rarely after the Federal Circuit tightened the standard in Therasense v. Becton Dickinson (2011). Belcher v. Hospira demonstrates that even under that demanding standard, when a patent applicant has access to material prior art through regulatory channels and deliberately omits it from USPTO disclosures, courts will find inequitable conduct.
For pharmaceutical and biotech companies, the case carries a practical warning: the duty of disclosure before the USPTO does not stop at the patent prosecution file. Information known to the company—even from FDA submissions, clinical trials, or regulatory correspondence—may be material to patentability and must be disclosed. Failure to do so can render an otherwise valid patent permanently unenforceable.